Cholinergic approaches to the treatment of progressive supranuclear palsy.
In spite of the severe loss of cholinergic neurons in the brains of patients with progressive supranuclear palsy (PSP), marginal or null benefits are seen in clinical trials after the administration of physostigmine, a cholinesterase inhibitor, or RS-86, a cholinergic agonist. The possible role of cholinergic therapy in PSP is reevaluated.
Neuroepidemiology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
I
I
Litvan
D018679:Cholinergic Agonists / Q000627:therapeutic use*; D006801:Humans; D010830:Physostigmine / Q000627:therapeutic use*; D013388:Succinimides / Q000627:therapeutic use*; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy*
D018679:Cholinergic Agonists; D013388:Succinimides; C001886:2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione; D010830:Physostigmine